Cargando…
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
PURPOSE: Oligometastasis is a state in which cancer patients have a limited number of metastatic tumors; patients with oligometastases survive longer than those with polymetastases. Extensive disease (ED)-small cell lung cancer (SCLC) is considered a systemic disease and a poor survival. This study...
Autores principales: | Shirasawa, Masayuki, Fukui, Tomoya, Kusuhara, Seiichiro, Harada, Shinya, Nishinarita, Noriko, Hiyoshi, Yasuhiro, Ishihara, Mikiko, Kasajima, Masashi, Igawa, Satoshi, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474590/ https://www.ncbi.nlm.nih.gov/pubmed/31002722 http://dx.doi.org/10.1371/journal.pone.0214599 |
Ejemplares similares
-
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019) -
Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018) -
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
por: Ono, Taihei, et al.
Publicado: (2019) -
Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer
por: Fukui, Tomoya, et al.
Publicado: (2019) -
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)